HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC

RecruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

September 16, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

December 30, 2025

Conditions

BCLC Stage B Hepatocellular CarcinomaBCLC Stage C Hepatocellular CarcinomaHepatic Arterial Infusion ChemotherapyLenvatinibPD-1Systemic Therapy

Interventions

PROCEDURE

hepatic artery infusion chemotherapy

Hepatic arterial infusion chemotherapy including FOLFOX and RALOX

DRUG

Lenvatinib + PD-1 monoclonal antibody

PD-1 inhibitors including Camrelizumab, Sintilimab, Tislelizumab

Trial Locations (1)

RECRUITING

The first hospital of China medical university, Shenyang

All Listed Sponsors

lead

First Hospital of China Medical University

OTHER